Big Pharma TPPA rhetoric obscures industry self-interest

Press Release – NZ Population Health Congress A recent analysis of patent-holding pharmaceutical industry statements about the Trans Pacific Partnership Agreement (TPPA) reveals that the rhetoric used is designed to mask the Industrys own interests and engender sympathy and support, at the …Big Pharma TPPA rhetoric obscures industry self-interest NZ Population Health Congress media release, 7 October 2014 A recent analysis of patent-holding pharmaceutical industry statements about the Trans Pacific Partnership Agreement (TPPA) reveals that the rhetoric used is designed to mask the Industry’s own interests and engender sympathy and support, at the expense of public health. The TPPA is a large regional trade agreement being negotiated by 12 countries, including New Zealand and the US. The research project explored how the industry has used language to frame the TPPA, influence opinion and exert leverage. University of Auckland researcher Briar Mannering told Congress delegates that the patent-holding pharmaceutical industry has been steadily lobbying for enhanced intellectual property protections and pricing controls to be included in the TPPA, that would raise the cost of medicines and reduce New Zealanders’ access to them. But, she said, much of the language used in this lobbying is disingenuous and deliberately designed to obscure the issues in its own favour. “For example, the Industry says the TPPA would create a ‘fairer regulatory environment’ for pharmaceutical companies whose interests are eroded by the availability of...

Read More